Windlas Biotech Ltd. benchmarking: Perfomance to industry peers

Financial

	Windlas Biotech	Bliss GVS Pharma	Shukra Pharma
Operational Metrics
Financials
5 yr Average ROE	10.64 %	6.83 %	14.12 %
5yr average Equity Multiplier	1.39	1.3	2.02
5yr Average Asset Turnover Ratio	1.07	0.62	0.6
5yr Avg Net Profit Margin	7.49 %	8.7 %	13.41 %
Price to Book	3.11	1.45	25.53
P/E	24.67	14.94	140.46
5yr Avg Cash Conversion Cycle	-12.87 Days	186.56 Days	-114.74 Days
Inventory Days	39.91 Days	54.35 Days	40.87 Days
Days Receivable	72.81 Days	189.93 Days	186.38 Days
Days Payable	93.99 Days	75.78 Days	342.97 Days
5yr Average Interest Coverage Ratio	42.87	14.68	23.9
5yr Avg ROCE	16.39 %	13.27 %	14.63 %
5yr Avg Operating Profit Margin	12.11 %	17.03 %	20.24 %
5 yr average Debt to Equity	0.05	0.11	0.23
5yr CAGR Net Profit	30.97 %	4.24 %	119.04 %
5yr Average Return on Assets	7.71 %	5.31 %	8.68 %
Shareholdings
Promoter Holding	61.99 %	35.39 %	50.96 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	2.04 %	0.84 %	1.79 %
Change in Mutual Fund Holding (3 Yrs)	-4.5 %	0.0	0.0

	Windlas Biotech	Bliss GVS Pharma	Shukra Pharma
Product Wise Break-Up	Product Wise Break-Up CDMO 76.25 Trade Generics & OTC 20.89 Exports 2.86 Anti Inflammatory 0 Anti-biotic 0 Anti-bacterial 0 Anti-fungal, 0 Antimalarial 0	Product Wise Break-Up Trade Generics & OTC 0 Antibiotics 5.0 Anti Malarials 43.0 Anti Inflammatory 7.0 CDMO 0 Anti-bacterial 0 Anti-fungal 16.0 Exports 0 Others 29.0	Product Wise Break-Up Trade Generics & OTC 0 Anti-biotic 0 Antimalarial 0 Anti Inflammatory 0 CDMO 0 Anti-bacterial 0 Anti-fungal, 0 Exports 0 Others 100
Location Wise Break-Up	Location Wise Break-Up India 95.68 Rest of the World 0 India 0 Others 4.32	Location Wise Break-Up India 6.61 Rest of the World 93.39	-
Acute vs Chronic	Acute vs Chronic Chronic & Sub-Chronic 59.0 Acute 41.0	-	-
Segment Wise Break-Up	Segment Wise Break-Up Pharmaceutical 100.0	-	-